PURETECH

GIVING LIFE TO SCIENCE®



2025 Annual Results

April 29, 2026

Important Information

The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question-and-answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by PureTech Health plc (the "Company"). The information in the Presentation is not intended to form the basis of any contract. By attending (whether in person or by telephone) or reading the Presentation, you agree to the conditions set out below.

THIS DOCUMENT AND THE PRESENTATION IS NOT A PROSPECTUS. The Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares or other securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any such offering of securities will only be made by means of a registration statement (including a prospectus) filed with the Securities and Exchange Commission (the "SEC"), after such registration statement becomes effective. No such registration statement has been filed as of the date of this presentation.

We report certain financial information using non-IFRS financial measures, as we believe these measures provide information that is useful to management and investors to assess financial performance. These non-IFRS financial measures do not have any standardized meaning and may not be comparable with similar measures used by other companies. For certain non-IFRS financial measures, there are no directly comparable amounts under IFRS. These non-IFRS financial measures should not be viewed as alternatives to measures of financial performance determined in accordance with IFRS. Please see slides 20-21 for a reconciliation of these measures to the most comparable IFRS measure.

This document and the Presentation contain statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the Exchange Act of 1934, as amended. These statements are based on our management's current beliefs, expectations and assumptions about future events, conditions and results, and on information currently available to us. This document and the Presentation also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

All statements other than statements of historical facts included in this document and the Presentation should be considered forward-looking statements, including without limitation, statements that relate to our expectations around our and our Founded Entities' therapeutic candidates and approach towards addressing major diseases, operational plans, future prospects, objectives, developments, strategies and expectations, the progress and timing of clinical trials and data readouts, the timing of regulatory approvals or clearances from the FDA, our future results of operations and financial outlook, including our anticipated cash runway and our forecasted cash, cash equivalents and short-term investments, and our ability to realize value for our shareholders.

Words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate," "think," "may," "could," "will," "would," "should," "continue," "potential," "likely," "opportunity" and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. Additionally, statements concerning future matters such as our expectations of business and market conditions, development and commercialization of new products, enhancements of existing products or technologies, and other statements regarding matters that are not historical are forward-looking statements.

The forward-looking statements are based on current expectations and currently available operating, financial and competitive information and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, the following: our history of incurring significant operating losses since our inception; our ability to realize value from our Founded Entities; our need for additional funding to achieve our business goals, which may not be available and which may force us to delay, limit or terminate certain of our therapeutic development efforts; our limited information about and limited control or influence over our Non-Controlled Founded Entities; the lengthy and expensive process of preclinical and clinical drug development, which has an uncertain outcome and potential for substantial delays; potential difficulties with enrolling patients in clinical trials, which could delay our clinical development activities; side effects, adverse events or other safety risks which could be associated with our therapeutic candidates and delay or halt their clinical development; our ability to obtain regulatory approval for and commercialize our therapeutic candidates; our ability to compete with companies currently marketing or engaged in the development of treatments for indications within our programs are designed to target; our ability to realize the benefits of our collaborations, licenses and other arrangements; the impact of government laws and regulations; our ability to maintain and protect our intellectual property rights; our reliance on third parties, including clinical research organizations, clinical investigators and manufacturers; our vulnerability to natural disasters, global economic factors, geo-political actions and unexpected events; and the risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future.

Given these risks, uncertainties and other factors, many of which are beyond the Company's control, you should not place undue reliance on these forward-looking statements.

Each forward-looking statement speaks only as at the date of this document. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

The Presentation is confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by its recipients to any other person for any purpose, other than with the consent of the Company.

By attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that: (i) you will not retain in any manner the Presentation or forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (ii) you have read and agree to comply with the contents of this notice.

Our Founded Entities are comprised of Founded Entities we control and Founded Entities we do not control, all of which are incorporated in the United States. We formed each of our Founded Entities and have been involved in development efforts in varying degrees. In the case of Founded Entities we control, we continue to maintain majority voting control. With respect to Founded Entities we do not control, we may benefit from appreciation in our minority equity investment as a shareholder of such companies.

Agenda



1. PureTech Strategy & Value Creation
2. Gallop Oncology Program Updates
3. Our Innovation Framework
4. Financial Highlights
5. Upcoming Catalysts

PureTech Strategy & Path to Value Creation

Robert Lyne
Chief Executive Officer

PureTech's Proven Hub-and-spoke Model

Strong Fundamentals

- Capital-efficient & self-funded model
- Deep clinical expertise
- Proven value-creation track record
  - ✓ 80% clinical success rate[1]
  - ✓ Three FDA approvals

De-risked, Differentiated Innovation

- Target clinically-validated therapeutics
- Rigorous de-risking & early go/no-go decisions
- Inventive step generates proprietary intellectual property



Maximize Stakeholder Benefits

- Deliver high-impact medicines for patients
- Maximize shareholder value through disciplined execution, durable growth, and thoughtful capital return

Value-driving Founded Entities

- Launch programs into Founded Entities
- Leverage external capital for efficient development
- Retain founding economics for significant upside

Celea THERAPEUTICS · SEAPORT THERAPEUTICS · GALLOP ONCOLOGY · COBENFY™

PURETECH
GIVING LIFE TO SCIENCE®

[1] The percentage includes number of successful trials out of all trials run for all therapeutic candidates advanced through at least Phase 1 by PureTech or its historical Founded Entities from 2009 onward.

Four Pillars of Asymmetric Value Creation

1 Streamlined Structure

- ***Operate on leaner & more efficient hub following Celea-financing***
- ***Delist from Nasdaq voluntarily to streamline spend & align with core trading***

2 Launch Founded Entities Early

- ***Establish & capitalize Founded Entities earlier to improve return on capital & amplify Founded Entity creation opportunities***

3 Refined Innovation Focus

- ***Sharpen focus on our differentiated framework to yield high-conviction opportunities (foundation of future Founded Entities)***

4 Commitment to Capital Returns

- ***Intend to return a greater proportion of future cash generation to shareholders in light of outsized return, while maintaining appropriate operational runway***

A Diversified Portfolio Well-Positioned for Significant Upside

	PureTech Economics		Clinical Maturity
	Equity[2]	**Non-dilutive**	
Celea Therapeutics	100%	Undisclosed	Phase 3 ready
Gallop Oncology	100%	Undisclosed	Phase 1b completed
Seaport Therapeutics *$733M post-money valuation following Series B financing[1]*	35.0%	3-5% tiered royalties on Glyph product net sales + modest regulatory & commercial milestones	Phase 2b ongoing
Karuna Therapeutics/ Cobenfy™	Acquired by BMS (March 2024)	2% royalty on annual Cobenfy sales above $2B + regulatory & commercial milestones	Commercial COBENFY™
New Innovation	Potential future Founded Entities		
Balance Sheet	~$248M PureTech level cash, cash equivalents as of March 31, 2026[3]		N/A

PURETECH
GIVING LIFE TO SCIENCE®

[1] Fully-diluted post-money valuation as of close of Series B on October 18, 2024; [2] Relevant ownership interests were calculated on a partially diluted basis (as opposed to a voting basis) as of December 31, 2025, including outstanding shares and stock options, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. PureTech controls Celea Therapeutics and Gallop Oncology, Inc.; [3] PureTech level cash and cash equivalents as of March 31, 2026, is an unaudited figured and excludes cash and cash equivalents at non-wholly owned subsidiary of $0.1m. PureTech level cash and cash equivalents is a non-IFRS measure.

Cobenfy™ Economics to PureTech Based on Analyst Forecasts

Potential ~$160 million in future economic value to PureTech between 2026-2033[1] based on analyst consensus for Cobenfy™ sales projections[2]

($ in millions)	2026	2027	2028	2029	2030	2031	2032	2033[1]
Low - High Analyst Consensus Range[2]	$260-900	$392-1,475	$490-1,978	$564-3,250	$620-4,750	$651-6,129	$651-7,303	$1,043-6,956
Average Cobenfy Analyst Consensus Sales Projections[2]	$343	$680	$1,189	$1,749	$2,365	$3,098	$3,659	$3,266
Annual Est. Royalties & Milestones to PureTech[3]	**$2**	**$42[4]**	**$25[4]**	**-**	**$7**	**$22**	**$33**	**$25**

- *2% royalty on annual Cobenfy sales above $2B*
- *Undisclosed regulatory & commercial milestones*

Projected Future Economics to PureTech **$156M**

Potential for significant upside upon approval in additional indications

Additional trial results from the ADEPT program in psychosis associated with Alzheimer's Disease by the end of 2026[5]

NOTE: These values do not reflect PureTech's views or assumptions and are provided for informational purposes only. Analyst consensus sales projections reported by Bloomberg may include sales estimates for additional indications for which Cobenfy is not currently approved. Future Cobenfy sales may differ materially from what is presented here based on a variety of factors.
[1] Estimated Cobenfy patent expiration (including Patent Term Extension) in October 2033 pending PTE approval, after which all PureTech's rights to milestone and royalty payments will terminate; corresponding annual sales are prorated through October in 2033; [2] Source: Bloomberg as of 4/7/2026. We give no opinion on the sales projections, which have been prepared by third parties independent of PureTech; [3] Annual Est. Royalties & Milestones to PureTech is based on 2% of the average Cobenfy analyst consensus sales projections over $2b annually per Bloomberg, plus management's probability-weighted estimate of milestone payments. They do not include any potential payments of sublicense income; [4] Commercial and regulatory milestone payments, which in certain cases are subject to undisclosed conditions & timeline and achievement of which have been probability weighted based on management assumptions; [5] Source: BMS December 3, 2025, press release, "*Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease*".

PURETECH
GIVING LIFE TO SCIENCE®

A Diversified Portfolio Well-Positioned for Significant Upside

	PureTech Economics		Clinical Maturity
	Equity[2]	**Non-dilutive**	
Celea Therapeutics	100%	Undisclosed	Phase 3 ready
Gallop Oncology	100%	Undisclosed	Phase 1b completed
Seaport Therapeutics *$733M post-money valuation following Series B financing[1]*	35.0%	3-5% tiered royalties on Glyph product net sales + modest regulatory & commercial milestones	Phase 2b ongoing
Karuna Therapeutics/ Cobenfy™	Acquired by BMS (March 2024)	2% royalty on annual Cobenfy sales above $2B + regulatory & commercial milestones	Commercial COBENFY™
New Innovation	Potential future Founded Entities		
Balance Sheet	~$248M PureTech level cash, cash equivalents as of March 31, 2026[3]		N/A

PURETECH
GIVING LIFE TO SCIENCE®

[1] Fully-diluted post-money valuation as of close of Series B on October 18, 2024; [2] Relevant ownership interests were calculated on a partially diluted basis (as opposed to a voting basis) as of December 31, 2025, including outstanding shares and stock options, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. PureTech controls Celea Therapeutics and Gallop Oncology, Inc.; [3] PureTech level cash and cash equivalents as of March 31, 2026, is an unaudited figured and excludes cash and cash equivalents at non-wholly owned subsidiary of $0.1m. PureTech level cash and cash equivalents is a non-IFRS measure.

Gallop Updates & Our Innovation Framework

Eric Elenko
Co-founder & President

Gallop Oncology (PureTech's Economic Interest: 100%)

Targeting galectin-9 to unlock new possibilities in cancer treatment

Galectin-9: A Groundbreaking Target

- An important oncogenic driver and potent immunosuppressor in cancer
- Promotes multiple immunosuppressive pathways
- Blocking galectin-9 results in tumor cell death as well as induction of anti-tumor immunity in the context of myeloid malignancies

LYT-200: A Mutation-Agnostic, Dual Mechanism of Action



Positive Topline Data from the Phase 1b Trial

GALLOP ONCOLOGY

Drives strategic prioritization of R/R HR-MDS with continued development planned in R/R AML

		LYT-200 in R/R HR-MDS *Proposed Phase 2 Dose* *12 mg/kg in Combination with HMA* *Efficacy Evaluable Patients[1] (N=11)*	**LYT-200 in R/R AML** *Proposed Phase 2 Dose* *12 mg/kg in Combination with VEN/HMA* *Efficacy Evaluable Patients[1] (N=26)*
Efficacy	Complete Response Rate	27.3%	30.8% Composite complete response rate[2]
	Partial Response Rate	9.1%	7.7%
	Marrow Complete Response Rate	9.1%	N/A
	Overall Response Rate	45.5%	42.3%
	Conversion to Transplant Rate	18.0%	19.2%

All study objectives achieved: (1) establish safety, (2) identify a dose for further development, and (3) determine indication prioritization based on the data

PURETECH
GIVING LIFE TO SCIENCE®

R/R = relapsed/refractory; HR-MDS = high-risk myelodysplastic syndrome; AML = acute myeloid leukemia; HMA = hypomethylating agents (azacitidine or decitabine); VEN = venetoclax. [1] Efficacy evaluable is defined in the protocol as all patients who received a minimum one full cycle of LYT-200 (four doses) and had a minimum of one post-baseline disease assessment. The intent-to-treat population for the R/R HR-MDS cohort was n=12 and for the R/R AML cohort was n=33; [2] Complete response + complete response with incomplete hematological recovery. Responders included patients with mutations associated with VEN resistance.

Strategic Prioritization of R/R HR-MDS

GALLOP ONCOLOGY

Guided by the high unmet need, lack of competition, and strong commercial opportunity

High Unmet Need

- MDS is a devastating disease with poor survival outcomes
- **Only one approved therapy** to treat R/R MDS[1], addressing only a small portion (~3-5%) of patients with a specific genetic mutation[2]

Favorable Competitive Landscape

- Sparse industry pipeline provides opportunity for Gallop to establish market leadership

Blockbuster Commercial Potential

- LYT-200 has the potential to capture substantial market share, given its strong efficacy and safety profile

[1] Tibsovo FDA label. Approved for patients with R/R MDS with a susceptible IDH1 mutation. [2] IDH1 mutation is found in 3-5% of MDS patients; Thol, Felicitas, et al. "IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis." Haematologica 95.10 (2010):1668..

Launching Innovation From Existing pharmacology

Deploying our L.I.F.E Model to systematically unlock therapeutic potential

Goals

- **Up to 3 concept-stage programs each year**
- **Up to 2 new development candidates over the next 3 years**

Approach



PURETECH
GIVING LIFE TO SCIENCE®

Financial Highlights & Upcoming Catalysts

Robert Lyne
Chief Executive Officer

2025 Financial Highlights

	DECEMBER 31, 2025 $ MILLIONS	DECEMBER 31, 2024 $ MILLIONS
Consolidated cash, cash equivalents and short-term investments	**277.3**	**367.3**
Less: cash & cash equivalents held at non-wholly owned subsidiaries	(0.2)	(0.5)
PureTech level cash, cash equivalents and short-term investments[1]	**277.1**	**366.8**
Revenue	4.7	4.8
Operating loss	(98.5)	(136.1)
Net Income / (loss) for the year	(110.1)	27.8

Definition of PureTech level cash, cash equivalents and short-term investments: Cash, cash equivalents and short-term investments held at PureTech Health plc and only wholly-owned subsidiaries as noted

Why we use it: PureTech Level Cash, cash Equivalents and short-term investments is a measure that provides valuable additional information with respect to cash, cash equivalents and short-term investments available to fund the Wholly Owned Programs and make certain investments in Founded Entities

PURETECH
GIVING LIFE TO SCIENCE®

[1] PureTech level cash, cash equivalents and short-term investments excludes cash and cash equivalents at non-wholly owned subsidiary of $0.5m. PureTech Level Cash, cash equivalents and short-term investments is a Non-IFRS measure. Please refer to slide 20-21 of this presentation for further information.

Near-term Priorities & Catalysts

	Equity[2]	Priority & Catalyst	Timing
Celea Therapeutics	100%	❑ Secure external funding & initiate Phase 3 SURPASS-IPF trial in IPF	By early Q3 2026
Gallop Oncology	100%	❑ Final results from Phase 1b trial in MDS/AML	H1 2026
		❑ Secure external funding	Q1 2027
Seaport Therapeutics *$733M post-money valuation following Series B financing[1]*	35.0%	❑ GlyphAllo: Topline data from Phase 2b BUOY-1 trial in patients with MDD with or without anxious distress	H1 2027
		❑ GlyphAgo: Initiate a Phase 2a proof-of-pharmacology trial in patients with GAD and sleep disturbance	Topline data by early 2028
		❑ GlyphAgo: Initiate a Phase 2b trial in patients with GAD	Topline data by end of 2028
Innovation	Fully owned by PureTech	❑ Innovation to build the next wave of programs	Ongoing
Balance Sheet	~$248M PureTech level cash, cash equivalents as of March 31, 2026[3]		

PURETECH
GIVING LIFE TO SCIENCE®

MDD = major depressive disorder; GAD = generalized anxiety disorder. [1] Fully-diluted post-money valuation as of close of Series B on October 18, 2024; [2] Relevant ownership interests were calculated on a partially diluted basis (as opposed to a voting basis) as of December 31, 2025, including outstanding shares and stock options, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. PureTech controls Celea Therapeutics and Gallop Oncology, Inc.; [3] PureTech level cash and cash equivalents as of March 31, 2026, is an unaudited figured and excludes cash and cash equivalents at non-wholly owned subsidiary of $0.1m. PureTech level cash and cash equivalents is a non-IFRS measure.

GIVING LIFE TO SCIENCE®

Thank You

PURETECH
GIVING LIFE TO SCIENCE®

Appendix

Financial Highlights

	March 31, 2026 $ millions	March 31, 2025 $ millions
Cash Flow and Liquidity		
Cash and Cash Equivalents	248.2	289.7
Short-term investments	0.0	49.8
Consolidated Cash, cash equivalents and short-term investments	**248.2**	**339.5**
Less: Cash and Cash Equivalents held at non-wholly-owned subsidiaries	(0.1)	(0.4)
PureTech Level Cash, cash equivalents and short-term investments[1]	**248.1**	**339.1**

[1] PureTech Level Cash, cash equivalents and short-term investments is a Non-IFRS measure.

Non-IFRS Measures

Reported Performance

Reported performance considers all factors that have affected the results of our business, as reflected in our consolidated financial statements.

Core Performance

Core performance measures are alternative performance measures (APM) which are adjusted and non-IFRS measures. These measures cannot be derived directly from our Consolidated Financial Statements. We believe that these non-IFRS performance measures, when provided in combination with reported performance, will provide investors, analysts and other stakeholders with helpful complementary information to better understand our financial performance and our financial position from period to period. The measures are also used by management for planning and reporting purposes. The measures are not substitutable for IFRS financial information and should not be considered superior to financial information presented in accordance with IFRS.

Cash flow and liquidity

PureTech Level Cash, cash equivalents and short-term investments

Measure type: Core performance.

Definition: Cash and cash equivalents, and Short-term investments held at PureTech Health plc and only wholly-owned subsidiaries.

Why we use it: PureTech Level Cash, cash equivalents and short-term investments is a measure that provides valuable additional information with respect to cash, cash equivalents and short-term investments available to fund the Wholly Owned Programs and make certain investments in Founded Entities.